Meiji Yasuda Asset Management Co Ltd. Increases Position in Solventum Corporation $SOLV

Meiji Yasuda Asset Management Co Ltd. increased its stake in Solventum Corporation (NYSE:SOLV) by 29.7% in the 4th quarter, Holdings Channel reports. The fund owned 32,482 shares of the company’s stock after buying an additional 7,430 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Solventum were worth $2,574,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC purchased a new position in Solventum in the third quarter worth $25,000. Hilltop National Bank grew its position in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. Deseret Mutual Benefit Administrators grew its position in Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares in the last quarter. JNBA Financial Advisors grew its position in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new position in Solventum in the second quarter worth $28,000.

Insider Activity

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.24% of the stock is owned by corporate insiders.

Solventum Price Performance

Shares of NYSE SOLV opened at $76.92 on Friday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company’s 50-day moving average is $68.68 and its 200 day moving average is $74.77. The stock has a market capitalization of $13.32 billion, a P/E ratio of 9.43, a P/E/G ratio of 1.19 and a beta of 0.59.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the previous year, the company earned $1.34 earnings per share. Solventum’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, sell-side analysts expect that Solventum Corporation will post 6.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SOLV shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Piper Sandler lowered their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company lowered their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Eight analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.